This article is more than 5 years old. Information may no longer be current.

VIDEO: Gene signature may guide adjuvant chemotherapy use in early-stage breast cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW ORLEANS — Lajos Pusztai, MD, DPhil, chief of breast medical oncology and co-director of the genetics, genomics and epigenetics program at Yale Cancer Center, spoke with HemOnc Today about the potential implications of the MINDACT trial.

Results of the randomized phase 3 trial showed a 70-gene signature called MammaPrint can help predict which patients with early-stage breast cancer will derive the most benefit from adjuvant chemotherapy.